Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.51 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.50 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27256088 | 0.91 | GRM5 (0.44) | GRM5VDAC2SLC7A11 | |
| SCHEMBL15457163 | 0.89 | VDAC2 (0.47) | VDAC2SLC7A11CYP3A4 | |
| SCHEMBL13633725 | 0.88 | SLC7A11 (0.61) | VDAC2SLC7A11 | |
| SCHEMBL15457164 | 0.82 | POLB (0.46) | VDAC2SLC7A11CYP3A4 | |
| SCHEMBL27256747 | 0.78 | GRM5 (0.43) | GRM5VDAC2SLC7A11 | |
| SCHEMBL27256089 | 0.78 | VDAC2 (0.54) | VDAC2SLC7A11 | |
| SCHEMBL13633652 | 0.77 | CACNA2D1 (0.43) | GRM5VDAC2SLC7A11 | |
| SCHEMBL15457166 | 0.76 | CASP1 (0.49) | CYP3A4 | |
| SCHEMBL15457088 | 0.76 | ALDH1A1 (0.46) | VDAC2SLC7A11 | |
| SCHEMBL15457169 | 0.76 | TP53 (0.49) | VDAC2SLC7A11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | GRM5 809/4885VDAC2 3980/4885SLC7A11 1250/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | GRM5 1038/4885VDAC2 2/4885SLC7A11 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.